儿童急性布鲁菌病伴转氨酶异常临床特征分析

doi:10.12372/jcp.2024.23e0662

Abstract

Abstract:

Objective The purpose of this study was to investigate the clinical characteristics of acute brucellosis with abnormal transaminase in children. Methods The data of 43 patients diagnosed with brucellosis from January 2015 to December 2021 were analyzed retrospectively. Based on transaminase values, the patients were divided into 2 groups: abnormal transaminase group and normal transaminase group. The clinical manifestations and laboratory indexes of two groups were analyzed. Result Abnormal transaminase was found in 74.41% of study group and mainly consist of mild and moderate abnormalities. The proportion of splenomegaly in abnormal transaminase group was higher than that in normal transaminase group (P<0.05). In the patients who had abnormal transaminase, the hemoglobin and platelet values were lower, and the blood culture positive rate were higher (P<0.05). The proportion of CD3⁺CD4^-CD8^-T cells was significantly higher than that of normal transaminase group (P<0.05) and the percentage of CD3⁺CD4^-CD8^-T cells was positively correlated with ALT and AST values (r=0.601, 0.466). The recovery time of transaminase was 1-3 weeks for mild abnormal transaminase, and 3-6 weeks for moderate and severe abnormal transaminase. Conclusion The proportion of children with acute brucellosis complicated with abnormal transaminase is higher, with mild and moderate abnormalities being predominant. Acute brucellosis complicated with abnormal transaminase in children has a favorable prognosis. Percentage of CD3⁺CD4^-CD8^-T cells may be related to abnormal transaminase in children with acute brucellosis.

Key words: acute brucellosis, abnormal transaminase, double negative T cells, child

JIA Yanhong, GUO Fang, WU Xiaoyuan, JIA Li, ZHAO Xin, LI Wenhui. Characteristic analysis of acute brucellosis in children with abnormal transaminase[J].Journal of Clinical Pediatrics, 2024, 42(11): 907-911.

Figures/Tables 3

References 29

[1]	《中华传染病杂志》编辑委员会. 布鲁菌病诊疗专家共识[J]. 中华传染病杂志, 2017, 35(12): 705-710.
[2]	Papadatos SS, Bazoukis G, Deligiannis G, et al. Respiratory symptoms as prominent manifestation of brucellosis: a case series[J]. J Clin Diagn Res, 2017, 11(5): OR01-OR03.
[3]	Agin M, Kayar Y. Demographic, laboratory, and clinical comparison of pediatric Brucella cases with and without liver involvement[J]. Cureus, 2020, 12(10): e10862.
[4]	张雁, 刘长民, 何晶晶. 151例伴肝损伤急性布鲁杆菌病患者的临床分析[J]. 国际流行病学传染病学杂志, 2017, 44(5): 357-359.
[5]	Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries[J]. Am J Gastroenterol, 2017, 112(1): 18-35. doi: 10.1038/ajg.2016.517 pmid: 27995906
[6]	张雨涵, 李飞, 施鹏, 等. 儿童原发性 EB病毒感染伴随转氨酶升高的相关因素及变化规律[J]. 中华儿科杂志, 2021, 59(8): 640-644.
[7]	Jiao H, Zhou Z, Li B, et al. The mechanism of facultative intracellular parasitism of Brucella[J]. Int J Mol Sci, 2021, 22(7): 3673.
[8]	郑旭, 邵丽萍, 刘恩才, 等. 布鲁氏菌的主要毒力因子及其致病机制[J]. 中华地方病学杂志, 2022, 41(3): 246-252.
[9]	Akritidis N, Tzivras M, Delladetsima I, et al. The liver in brucellosis[J]. Clin Gastroenterol Hepatol, 2007, 5(9): 1109-1112.
[10]	Shrestha S, Karn M, Regmi SM, et al. Clinical profile and biochemical abnormalities in brucellosis: A cross-sectional study[J]. Ann Med Surg (Lond), 2022, 79: 103922.
[11]	Sahinturk H, Baran B, Sisman G, et al. Liver involvement is associated with blood culture positivity and high agglutination titre in patients with brucellosis in Turkey[J]. J Med Microbiol, 2018, 67(8): 1078-1082. doi: 10.1099/jmm.0.000791 pmid: 29972349
[12]	常彩花, 连江山, 张永萍. 伴有肝损害的301例急性布鲁菌病患者的流行病学和临床特征分析[J]. 中华临床感染病杂志, 2021, 14(5): 364-367.
[13]	Ma L, Ma J, Chen X, et al. A 10-year retrospective comparative analysis of the clinical features of brucellosis in children and adults[J]. J Infect Dev Ctries, 2021, 15(8): 1147-1154.
[14]	Albayrak A, Albayrak F. Hepatic granulomas associated with brucellosis: Hepatic granulomas and brucellosis[J]. Hepat Mon, 2011, 11(1): 1-2. pmid: 22087106
[15]	Tanir G, Tufekci SB, Tuygun N. Presentation, compli-cations, and treatment outcome of brucellosis in Turkish children[J]. Pediatr Int, 2009, 51(1): 114-119.
[16]	Bukhari EE. Pediatric brucellosis. An update review for the new millennium[J]. Saudi Med J, 2018, 39(4): 336-341. doi: 10.15537/smj.2018.4.21896 pmid: 29619483
[17]	Hassouneh L, Quadri S, Pichilingue-Reto P, et al. An outbreak of brucellosis: an adult and pediatric case series[J]. Open Forum Infect Dis, 2019, 6(10): ofz384.
[18]	Yoldas T, Tezer H, Ozkaya-Parlakay A, et al. Clinical and laboratory findings of 97 pediatric brucellosis patients in central Turkey[J]. J Microbiol Immunol Infect, 2015, 48(4): 446-449. doi: 10.1016/j.jmii.2014.04.016 pmid: 25092047
[19]	Durward M, Radhakrishnan G, Harms J, et al. Active evasion of CTL mediated killing and low quality responding CD8⁺ T cells contribute to persistence of brucellosis[J]. PLoS One, 2012, 7(4): e34925.
[20]	Bahador A, Hadjati J, Hassannejad N, et al. Frequencies of CD4⁺ T regulatory cells and their CD25(high) and FoxP3(high) subsets augment in peripheral blood of patients with acute and chronic brucellosis[J]. Osong Public Health Res Perspect, 2014, 5(3): 161-168.
[21]	Amjadi O, Rafiei A, Mardani Mi, et al. A review of the immunopathogenesis of Brucellosis[J], Infect Dis (Lond), 2019, 51(5): 321-333.
[22]	Bessoles S, Ni M, Garcia-Jimenez S, et al. Role of NKG2D and its ligands in the anti-infectious activity of Vγ9Vδ2 T cells against intracellular bacteria[J]. Eur J Immunol, 2011, 41(6): 1619-1628. doi: 10.1002/eji.201041230 pmid: 21469127
[23]	Delpino MV, Barrionuevo P, Scian R, et al. Brucella-infected hepatocytes mediate potentially tissue-damaging immune responses[J]. J Hepatol, 2010, 53(1): 145-154. doi: 10.1016/j.jhep.2010.02.028 pmid: 20452697
[24]	Giambartolomei GH, Delpino MV. Immunopathogenesis of hepatic brucellosis[J]. Front Cell Infect Microbiol, 2019, 9: 423.
[25]	Fischer K, Voelkl S, Heymann J, et al. Isolation and characterization of human antigen-specific TCRαβ⁺ CD4^- CD8^- double-negative regulatory T cells[J]. Blood, 2005, 105(7): 2828-2835. doi: 10.1182/blood-2004-07-2583 pmid: 15572590
[26]	Hu SH, Zhang LH, Gao J, et al. NKG2D enhances double-negative T cell regulation of B cells[J]. Front Immunol, 2021, 12: 650788.
[27]	Wu Z, Zheng Y, Sheng J, et al, CD3⁺CD4^-CD8^-(Double-Negative) T cells in inflammation, immune disorders and cancer[J]. Front Immunol, 2022, 13: 816005.
[28]	Getachew Y, Cusimano FA, James LP, et al. The role of intrahepatic CD3⁺/CD4^-/CD8^- double negative T (DN T) cells in enhanced acetaminophen toxicity[J]. Toxicol Appl Pharmacol, 2014, 280(2): 264-271.
[29]	Zhou QH, Wu FT, Pang LT, et al. Role of γδT cells in liver diseases and its relationship with intestinal microbiota[J]. World J Gastroenterol, 2020, 26(20): 2559-2569.

组别	转氨酶异常组(n=32)	转氨酶正常组(n=11)	统计量	P
性别（男/女）	22/10	6/5	χ²=0.24	0.627
年龄[M(P₂₅~P₇₅)]/岁	6.0（4.0~10.5）	9.0（5.0~12.0）	Z=1.11	0.268
发热[n(%)]	31（96.87）	11（100）	χ²=0.00	1.000
关节痛（有/无）	5/27	1/10	χ²=0.00	0.972
肝肿大（是/否）	14/18	2/9	χ²=1.33	0.249
脾肿大（是/否）	22/10	3/8	χ²=4.21	0.040
入院前时间[M(P₂₅~P₇₅)]/d	12.0（7.0~20.0）	15.0（10.0~30.0）	Z=0.99	0.321
住院时间[M(P₂₅~P₇₅)]/d	12.0（9.3~15.8）	11.0（9.0~16.0）	Z=0.27	0.791

项目	转氨酶异常组（n=32）	转氨酶正常组（n=11）	统计量	P
WBC[M(P₂₅~P₇₅)]/×10⁹·L^-1	6.65（5.02~7.87）	6.5（4.90~8.90）	Z=0.36	0.717
HGB[M(P₂₅~P₇₅)]/g·L^-1	113（105.25~121.00）	120（116.00~125.00）	Z=2.40	0.017
PLT[M(P₂₅~P₇₅)]/×10⁹·L^-1	187.34±82.21	281.54±80.58	t=3.29	0.002
TB[M(P₂₅~P₇₅)]/μmol·L^-1	5.35（3.70~6.70）	6.00（4.00~7.80）	Z=0.38	0.707
PD[M(P₂₅~P₇₅)]/μmol·L^-1	2.35（1.90~4.00）	2.60（2.00~3.20）	Z=0.14	0.889
GGT[M(P₂₅~P₇₅)]/U·L^-1	27.50（14.50~54.75）	19.00（15.00~24.00）	Z=1.56	0.119
CRP[M(P₂₅~P₇₅)]/mg·L^-1	8.88（3.06~13.68）	3.45（0.50~14.73）	Z=1.53	0.126
ESR[M(P₂₅~P₇₅)]/mm·h^-1	15.00（8.25~24.50）	9.00（5.00~33.00）	Z=0.96	0.336
血培养（阳性/阴性）	28/4	5/6	χ²=5.92	0.015

组别	例数	CD3⁺ ($\bar{x} \pm s$)	CD4⁺ [M(P₂₅~P₇₅)]	CD8⁺ ($\bar{x} \pm s$)	CD3⁺CD4^-CD8^- ($\bar{x} \pm s$)	CD3⁺CD4⁺CD8⁺ [M(P₂₅~P₇₅)]	CD19⁺ [M(P₂₅~P₇₅)]	CD56⁺ [M(P₂₅~P₇₅)]
转氨酶异常组	32	81.27±7.63	31.95 （29.80~34.97）	32.06±6.94	15.92±6.65	0.10（0.00~0.20）	9.55 （5.40~16.47）	4.35 （3.05~7.37）
转氨酶正常组	11	79.18±6.16	37.5 （30.10~38.60）	33.50±8.01	10.98±3.69	0.10（0.10~0.20）	15.40 （6.70~18.30）	4.90 （4.50~5.80）
统计量		t=0.81	Z=1.49	t=0.57	t=2.34	Z=0.52	Z=0.91	Z=0.40
P		0.421	0.136	0.573	0.024	0.600	0.366	0.691

Characteristic analysis of acute brucellosis in children with abnormal transaminase

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 29

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LUO Mingjing, YU Jiaming, WANG Xiaodong, ZHANG Xiaoling, YU Yue, ZHANG Yu, WEN Feiqiu, LIU Sixi. Clinical analysis of invasive fungal disease secondary to allogeneic hematopoietic stem cell transplantation in 424 children with thalassemia [J]. Journal of Clinical Pediatrics, 2025, 43(1): 21-28.
[2]	LIU Dongxia, JIN Rong, LIN Rongjun. Risk factors analysis of severe refractory Mycoplasma pneumoniae pneumonia complicated with bronchitis obliterans in children [J]. Journal of Clinical Pediatrics, 2025, 43(1): 29-34.
[3]	ZHONG Jinhong, WANG Can, CHEN Fang. Progress in the research of infantile fiberoptic bronchoscopy sedation [J]. Journal of Clinical Pediatrics, 2025, 43(1): 50-55.
[4]	JIANG Weiqin, WANG Jing, CHENG Anna, CHEN Tingting, HUANG Yujuan. Predictors of recurrent febrile seizures during the same febrile illness in children with febrile seizures [J]. Journal of Clinical Pediatrics, 2025, 43(1): 8-13.
[5]	QIU Xiu, WEI Dongmei, LIN Shanshan, XIA Huimin, ZHOU Wenhao. Principles and practice of the Born in Guangzhou Cohort Study [J]. Journal of Clinical Pediatrics, 2024, 42(9): 747-752.
[6]	FAN Jianxia. The origins and development of the healthy life trajectory program: a cohort of community-family-mother-child multidimensional interventions for overweight and obesity in children [J]. Journal of Clinical Pediatrics, 2024, 42(9): 768-773.
[7]	JIANG Tao, LI Shuangjie, TANG Lian, OUYANG Wenxian. Immunobiological properties of peripheral blood MAIT cells in children with chronic hepatitis B [J]. Journal of Clinical Pediatrics, 2024, 42(9): 787-790.
[8]	ZHOU Jie, LIU Keqiang, WANG Jinling, WANG Ying. Megacystis-microcolon-intestinal hypoperistalsis syndrome caused by MYH11 elongating mutation : a case report and literatures review [J]. Journal of Clinical Pediatrics, 2024, 42(9): 798-804.
[9]	CHU Sijia, TANG Jihong. Research progress of central nervous system injury associated with pediatric acute lymphoblastic leukemia and its treatment [J]. Journal of Clinical Pediatrics, 2024, 42(9): 811-816.
[10]	DING Yaping, XIA Shanshan, ZHANG Chenmei. Interpretation of “2023 Children’s Renal Nutrition Working Group Clinical Practice Recommendations: Nutritional Management of Children with Acute Kidney Injury” [J]. Journal of Clinical Pediatrics, 2024, 42(8): 667-672.
[11]	LI Yirong, LI Huiping, GAO Jingyu, XIAO Yuhua, CHEN Xiaomin, LU Yanling, ZHAO Nana, FENG Xiaoqin. Comparison of different doses of cytarabine for induction chemotherapy in children with acute myeloid leukemia in FLAG-IDA regimen [J]. Journal of Clinical Pediatrics, 2024, 42(8): 673-677.
[12]	HUANG Bo, DONG Yanying, SONG Linlan. Clinical characteristics of 348 children with infectious mononucleosis [J]. Journal of Clinical Pediatrics, 2024, 42(8): 678-683.
[13]	WANG Dan, SHAO Jingbo, LI Hong, ZHANG Na, ZHU Jiashi, FU Pan, WANG Zhen. Clinical analysis of 38 cases of hematological malignancies complicated with tumor lysis syndrome in children [J]. Journal of Clinical Pediatrics, 2024, 42(8): 684-690.
[14]	MA Yan, WEI Xingjiao, BAI Hua, ZHANG Yan, TIAN Xinmin, Aqsa Ahmad, LIANG Lijun. Analysis of etiological composition and clinical features of stage 5 chronic kidney disease in children in a tertiary hospital in western China [J]. Journal of Clinical Pediatrics, 2024, 42(8): 697-703.
[15]	WANG Ye, ZHANG Linlin, CHI Zuofei, SUN Ruowen, JIANG Zehui, XU Gang. A case of clinical report of T-lymphoblastic lymphoma secondary to acute promyelocytic leukemia in children [J]. Journal of Clinical Pediatrics, 2024, 42(8): 722-727.